TAMPA, Fla. – Moffitt Cancer Center is one of three facilities collaborating with Princess Margaret Cancer Centre in thePrincess Margaret Phase I Consortium. The consortium is a result of a five-year UM1 grant from the National Cancer Institute. UM1 grants support large-scale collaborative research activities, such as clinical trial networks.
Phase I studies involve the most novel clinical science. The trials test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range and identify any possible side effects. Working as a team, the consortium will have more access to patients who may qualify for these phase I studies and improve the potential for larger phase II and phase III studies.
The consortium will be overseen by Princess Margaret’s Lillian L Siu, M.D., F.R.C.P.C. Dan Sullivan, M.D., will serve as Moffitt’s principal investigator with collaboration from Richard Lush, Ph.D. and Amit Mahipal, M.D. The two other facilities participating in the consortium are Juravinski Cancer Centre and British Columbia Cancer Agency.
“This is an innovative collaboration that will further personalized cancer care,” said Sullivan. “Patients participating in our early phase studies will undergo genomic screening that will help us identify drivers of drug sensitivity or resistance. We can then use that information to help identify and correlate gene markers with clinical outcome.”
About Moffitt Cancer Center
Located in Tampa, Moffitt is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt is the top-ranked cancer hospital in the Southeast and has been listed in U.S. News & World Report as one of the “Best Hospitals” for cancer since 1999. With more than 4,500 employees, Moffitt has an economic impact on Florida of nearly $1.6 billion. For more information, visit MOFFITT.org, and follow the Moffitt momentum on Facebook, Twitter and YouTube.